# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Barclays analyst Luke Sergott maintains Twist Bioscience (NASDAQ:TWST) with a Overweight and lowers the price target from $4...
On Monday, Cathie Wood-led Ark Invest adjusted its portfolio, notably selling shares of cryptocurrency-related companies such a...
Twist for Element, Exome 2.0 plus Comprehensive Exome Spike-in Workflow expected to be available soon
High accuracy and detection to identify tumor variants from degraded and low input samples as well as samples with limited DNA ...